Following President Biden’s Oct. 6 announcement that his administration will review the status of cannabis under federal law, the industry is now wondering: What does that mean for us?

This review could ultimately result in rescheduling the plant to another classification under the Controlled Substances Act or descheduling the plant entirely—or nothing may happen at all.

During this FREE and LIVE webinar produced by Cannabis Business Times and Cannabis Conference on Nov. 7 at 1 p.m. ET, a panel of expert industry stakeholders will discuss the practical consequences of this federal crossroads—and how licensed businesses can prepare for the future. Attendees will learn about:

• The actual process that the Biden administration is undertaking
• The ways in which rescheduling or descheduling cannabis would impact the industry
• The ways in which businesses can secure GMP compliance ahead of possible FDA oversight
• The ways in which access to capital may change under federal intervention
• The possible effects on interstate commerce and international trade
• And more: Bring your questions!